Morgan Stanley Maintains Equal-Weight on Third Harmonic Bio, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz maintains an Equal-Weight rating on Third Harmonic Bio (NASDAQ:THRD) and raises the price target from $5 to $7.
August 11, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Third Harmonic Bio and raises the price target from $5 to $7.
The news is directly about Third Harmonic Bio. The raised price target by Morgan Stanley indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100